Outlook Therapeutics Inc. Overview
Outlook Therapeutics, Inc., a clinical-stage biopharmaceutical company, is making strides in the biotechnology sector with its focus on developing complex biosimilar therapeutics. The company specializes in monoclonal antibodies targeting immunology and oncology, two critical areas in healthcare. Based in Iselin, United States, Outlook Therapeutics operates within the Health Care sector and is listed on the Nasdaq stock exchange.
Recent Financial Performance
As of May 12, 2025, the close price of Outlook Therapeutics’ stock was $2.03. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $9.25 on July 16, 2024, and a 52-week low of $0.87 on November 26, 2024. The company’s market capitalization stands at approximately $50,561,277 USD.
Company Background
Outlook Therapeutics went public on the Nasdaq stock exchange on May 13, 2016. Since then, it has focused on identifying, developing, manufacturing, and commercializing biosimilar therapeutics, particularly monoclonal antibodies. These efforts are concentrated in the immunology and oncology fields, aiming to provide innovative treatments for complex diseases.
Industry Position
As part of the biotechnology industry, Outlook Therapeutics is positioned to contribute to advancements in healthcare through its specialized focus on biosimilars. The company’s strategic initiatives in monoclonal antibody development highlight its commitment to addressing unmet medical needs in immunology and oncology.
Conclusion
Outlook Therapeutics, Inc. continues to navigate the dynamic biotechnology landscape with its focus on biosimilar therapeutics. Despite recent stock price fluctuations, the company remains dedicated to its mission of developing innovative treatments in the immunology and oncology sectors. With its base in Iselin and presence on the Nasdaq, Outlook Therapeutics is poised to make significant contributions to the healthcare industry.